Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes

Michael A Via1, Himani Chandra2, Takako Araki1, Matthew V Potenza3, Maria Skamagas41Division of Endocrinology and Metabolism, Albert Einstein College of Medicine, Beth Israel Medical Center, New York, NY, USA; 2Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, Jam...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Via MA
Format: article
Langue:EN
Publié: Dove Medical Press 2010
Sujets:
Accès en ligne:https://doaj.org/article/cb1201f357514f8c890611a7afef052d
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!